Clinical Trials on Chronic Hepatitis C (CHC) in Portugal

Total 29 results

AbbVie

Completed

A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis (EXPEDITION-8)

Hepatitis C Virus (HCV)

United States, Bulgaria, Canada, Czechia, France, Greece, Hungary, Ireland, Israel, Italy, Poland, Portugal, Puerto Rico, Romania, Russian Federation, Spain, Taiwan, United Kingdom, Vietnam
Centro Hospitalar Lisboa Norte

Unknown

Psychobiological Characterization of Depression in Hepatitis C

Depression | Hepatitis c

Portugal
AbbVie

Completed

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)

Chronic Hepatitis C Virus (HCV) Infection Genotype 1

Algeria, Australia, Belgium, Bulgaria, Canada, Denmark, Finland, France, Germany, Greece, Israel, Italy, Mexico, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Saudi Arabia, Spain, Switzerland, Turkey, Austria, Ireland and more
AbbVie

Completed

Study of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1 to 6

Hepatitis C

Austria, Belgium, France, Greece, Israel, Italy, Poland, Portugal, Switzerland
Janssen-Cilag International NV

Completed

Telaprevir Open-Label Study in Co-Infected Patients

Hepatitis C, Chronic

United Kingdom, Belgium, Germany, Portugal, Russian Federation, Hungary, Ireland, Luxembourg
Boehringer Ingelheim

Completed

Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection

Hepatitis C, Chronic

United States, Australia, Austria, France, Germany, New Zealand, Portugal, Romania, Spain, Switzerland
Janssen R&D Ireland

Completed

A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1

Hepatitis C Virus Genotype-1

United States, France, United Kingdom, Germany, Spain, Portugal, Canada, Puerto Rico
Boehringer Ingelheim

Completed

IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1

Hepatitis C, Chronic

United States, Austria, Canada, France, Germany, Hungary, Ireland, Italy, Netherlands, Portugal, Romania, Russian Federation, Spain, United Kingdom
Boehringer Ingelheim

Completed

Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2

Hepatitis C, Chronic

United States, Australia, Belgium, Canada, France, Germany, Greece, Italy, New Zealand, Portugal, Spain, United Kingdom
Hoffmann-La Roche

Completed

REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy

Hepatitis C, Chronic

Belgium, France, Germany, Italy, Spain, Sweden, United States, Greece, Portugal, Turkey, Switzerland, Canada, United Kingdom, Brazil
Boehringer Ingelheim

Completed

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)

Hepatitis C, Chronic

United States, Austria, Belgium, Canada, France, Germany, Japan, Portugal, Puerto Rico, Spain, Switzerland, United Kingdom
Hoffmann-La Roche

Completed

A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C

Hepatitis C, Chronic

Belgium, France, Germany, Sweden, Switzerland, Turkey, Greece, Taiwan, Estonia, Slovakia, Italy, Romania, Lithuania, Serbia, Portugal, Egypt, Pakistan, Mexico, Peru, Lebanon, United States, Argentina, Chile, Kuwait, Latvia, Macedonia, The... and more
Hoffmann-La Roche

Completed

An Observational Study on The Prediction of Adverse Events in Patients With Chronic Hepatitis C Receiving a Long-Acting Interferon Plus Ribavirin (GUARD-C)

Hepatitis C, Chronic

Belgium, Greece, Slovakia, Hungary, Italy, Korea, Republic of, Poland, Romania, Bosnia and Herzegovina, Serbia, Brazil, Morocco, Portugal, India, Egypt, Pakistan, Lebanon, Kuwait, Macedonia, The Former Yugoslav Republic of, Qatar and more
Hoffmann-La Roche

Completed

An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C

Hepatitis C, Chronic

Belgium, France, Germany, Sweden, Switzerland, Turkey, Greece, Ireland, Taiwan, Estonia, Hungary, Italy, Romania, United Kingdom, Serbia, Morocco, Portugal, Saudi Arabia, Egypt, Pakistan, Lebanon, Macedonia, The Former Yugoslav Republic... and more
Boehringer Ingelheim

Completed

Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)

Hepatitis C, Chronic

United States, Argentina, Australia, Austria, Canada, Czech Republic, France, Germany, Korea, Republic of, Netherlands, Portugal, Romania, Spain, Switzerland, United Kingdom
Hoffmann-La Roche

Terminated

Effect of RO7049665 on the Time to Relapse Following Steroid Tapering in Participants With Autoimmune Hepatitis (AIH)

Autoimmune Hepatitis | Autoimmune Chronic Hepatitis

Canada, United Kingdom, Korea, Republic of, Australia, Germany, Italy, Netherlands, Portugal
Janssen Pharmaceutica N.V., Belgium

Withdrawn

A Study in Chronic Hepatitis B e-Antigen Negative Participants After Discontinuation of Nucleos(t)Ide Analog (NA) Treatment (SALMONS)

Hepatitis B, Chronic

Germany, France, Italy, Spain, Denmark, Portugal, Greece
Janssen R&D Ireland

Completed

An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants (QUEST-2)

Hepatitis C

United States, France, Poland, Belgium, Germany, Spain, Portugal, Bulgaria, Turkey, Argentina, Brazil, Austria, Netherlands, Slovakia, Puerto Rico
Gilead Sciences

Completed

Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B

Chronic Hepatitis B

Korea, Republic of, Hong Kong, Spain, Taiwan, United States, Poland, France, Netherlands, Singapore, Australia, Canada, Italy, United Kingdom, Germany, Portugal, Romania, Greece, Turkey, India
Janssen R&D Ireland

Completed

A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study

Hepatitis C

United States, Australia, France, Ukraine, United Kingdom, Belgium, Germany, Spain, Israel, Portugal, Bulgaria, Netherlands, Canada, New Zealand, Russian Federation, Argentina, Brazil, Puerto Rico, Austria, Poland, Romania, Mexico
Tibotec Pharmaceuticals, Ireland

Completed

A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment (ASPIRE)

Hepatitis C

United States, Australia, France, United Kingdom, Belgium, Germany, Israel, Portugal, Canada, New Zealand, Russian Federation, Austria, Poland, Norway
Bristol-Myers Squibb

Completed

Study of Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection

Chronic Hepatitis B

Brazil, Canada, China, France, India, Italy, Korea, Republic of, Mexico, Poland, Russian Federation, Taiwan, Thailand, Turkey, United States, Colombia, Germany, Spain, Czechia, Greece, Romania, Argentina, Philippines, Singapore, Portugal
Boehringer Ingelheim

Completed

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1)

Hepatitis C

Austria, Belgium, France, Germany, Japan, Portugal, Romania, Russian Federation, Spain, Switzerland, United Kingdom
Boehringer Ingelheim

Completed

A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients

Hepatitis C

United States, Austria, Belgium, Canada, France, Germany, Japan, Korea, Republic of, Portugal, Romania, Russian Federation, Spain, Switzerland, Taiwan, United Kingdom
Hoffmann-La Roche

Completed

A Study to Collect Blood Biomarker Samples From Participants With Chronic Hepatitis B (CHB) Who Received Treatment With Pegasys (Peginterferon Alfa-2a) ± Nucleoside/Nucleotide Analogue

Hepatitis B, Chronic

Thailand, China, Italy, United Kingdom, Korea, Republic of, Taiwan, Austria, Bulgaria, Germany, New Zealand, France, Poland, Portugal, Romania, Greece
Janssen R&D Ireland

Completed

TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy (ATTAIN)

Hepatitis C

United States, Australia, France, Poland, United Kingdom, Germany, Spain, Belgium, Israel, Portugal, Bulgaria, Romania, Denmark, Greece, Sweden, Canada, Czech Republic, Argentina, Brazil, Austria, Hungary, Switzerland, Puerto Rico, No...
Hoffmann-La Roche

Completed

An Observational Cohort Study in Patients With Chronic Hepatitis B Receiving Pegasys

Hepatitis B, Chronic

United Kingdom, Indonesia, Thailand, India, China, Korea, Republic of, Austria, France, Germany, Saudi Arabia, Hong Kong, Bulgaria, New Zealand, Lebanon, Bahrain, Bangladesh, Bosnia and Herzegovina, Egypt, Ireland, Jordan, Macedonia... and more
Rigshospitalet, Denmark
University College, London

Enrolling by invitation

EuroSIDA - Clinical and Virological Outcome of European Patients Infected With HIV (EuroSIDA)

End Stage Liver Disease | Cardiovascular Diseases | Fractures, Bone | Diabetes Mellitus | Renal Insufficiency | Hepatitis B | Hepatitis C | Kidney Failure, Chronic | Proteinuria | HIV | Coinfection | Acidosis, Lactic | AIDS

Spain, Switzerland, Germany, United Kingdom, Austria, Sweden, Finland, Israel, Denmark, France, Italy, Iceland, Belgium, Slovakia, Norway, Lithuania, Portugal, Poland, Croatia, Czechia, Greece, Hungary, Luxembourg, Argentina, Belarus, Bosnia... and more
Novartis Pharmaceuticals

Completed

A Prospective Evaluation of Natriuretic Peptide Based Referral of CHF Patients in Primary Care (PREFER)

Chronic Heart Failure (CHF)

Croatia, Russian Federation, Belgium, Slovenia, Spain, Lithuania, Estonia, Hungary, France, Latvia, Norway, Cyprus, Denmark, Israel, Italy, Malta, Poland, Portugal

Clinical Trials on Chronic Hepatitis C (CHC) in Portugal

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations